Healthcare
AstraZeneca Invests $2 Billion in Summit Therapeutics: Strategic Entry into Cancer Market
The British-Swedish pharmaceutical group AstraZeneca secures around 12 percent of Summit Therapeutics for $2.0 billion. Summit shares rose sharply after hours. What retail investors need to know about the oncology deal.